AVTX
$15.38
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to ...
Recent News
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference
Avalo Therapeutics (NASDAQ:AVTX) CEO Garry Neil said the company expects to report top-line data in the second quarter from its completed Phase 2b LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS), outlining what he described as operational execution milestones in 2025 and the rationale for t
Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference
Avalo Therapeutics (NASDAQ:AVTX) used a presentation at its 46th Annual Healthcare Conference appearance to outline its strategy for AVTX-009, a high-affinity human monoclonal antibody designed to neutralize interleukin-1 beta (IL-1β), and to discuss how upcoming Phase II data in hidradenitis suppur
Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference
Avalo Therapeutics (NASDAQ:AVTX) Chief Executive Officer Dr. Garry Neil discussed the company’s hidradenitis suppurativa (HS) program and upcoming clinical catalyst during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. The discussion focused on Avalo’s lead candida
Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa
Avalo Therapeutics (NASDAQ:AVTX) is preparing to report phase IIb data in the second quarter of 2026 from its LOTUS trial evaluating AVTX-009 in hidradenitis suppurativa (HS), CEO Garry Neil said during a fireside chat at Guggenheim’s Emerging Outlook Biotech Summit 2026. Neil described LOTUS as a
Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX)
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is one of the top long-term biotechnology stocks to buy. On October 17, Piper Sandler analyst Yasmeen Rahimi reaffirmed her Buy rating on Avalo Therapeutics Inc. (NASDAQ:AVTX), maintaining a price target of $48, which implies a substantial upside potential of 167.86% from the stock’s current trading levels. The buy stance underscores […]